Methods of Application：
1.Simultaneous application using Connected Mixing System 2. Sequential Application
FIBINGLURAAS® consists of fibrinogen/FXIII and thrombin prepared from human plasma. Mixture of two components simulates the last phase of blood coagulation, activation of fibrinogen by thrombin and crosslinking of fibrin monomers to fibrin polymers leads to hemostasis before or after surgery and tissue glue.
Innovative introduction of new drainage tools such as "return" type drainage pipe and drainage fixing device of patented products to reduce the risk of drainage.
blood urea N:8.56mol/L
Hirudin is the most potent natural inhibitor of thrombin. Unlike antithrombin, hirudin binds to and inhibits only the activated thrombin, with a specific activity on fibrinogen.Therefore, hirudin prevents or dissolves the formation of clots and thrombi , and has therapeutic value in blood coagulation disorders, in the treatment of skin hematomas and of superficial varicose veins, either as an injectable or a topical application cream. In some aspects, hirudin has advantages over more commonly used anticoagulants and thrombolytics, such as heparin, as it does not interfere with the biological activity of other serum proteins, and can also act on complexed thrombin.
Methods of Application：Subcutaneous injection. Prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent (sterile water for injection). After reconstitution, the final concentration of Tiluoting (thymalfasin) is 1.6 mg/ml.
Tiluoting’s effects on TLR9 lead to stimulation of the NFkappaB and p38 MAPK pathways, increased expression of the thymopoetic cytokines IFNα, IL-7, and IL-15, and stimulated macrophage activation and activity. Tiluoting stimulates the activity of indoleamine-2,3-dioxygenase (IDO) in plasmacytoid DCs, hence dampening immune response to prevent a pro-inflammatory cytokine storm and possibly autoimmune phenomena.